ST6GALNAC1
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1
Protein Summary
Glycosylation of proteins affects cell-cell interaction, interactions with the matrix, and the functions of intracellular molecules. ST6GALNAC1 transfers a sialic acid, N-acetylneuraminic acid (NeuAc), in an alpha-2,6 linkage to O-linked GalNAc residues. The cancer-associated sialyl-Tn (sTn) antigen is formed by ST6GALNAC1-catalyzed sialylation of GalNAc residues on mucins (Ikehara et al., 1999 [PubMed 10536037]; Sewell et al., 2006 [PubMed 16319059]).[supplied by OMIM, Mar 2008]
- ENST00000156626
- ENSP00000156626
- ENSG00000070526
- SIAT7A
- STYI
- SIAT7A
- HSY11339
- ST6GalNAcI
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
tissue sample | 0.62 | ||
tissue | 0.56 | ||
virus perturbation | 0.55 | ||
cellular component | 0.54 | ||
pathway | 0.52 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 205.99 (req: < 5)
Gene RIFs: 14 (req: <= 3)
Antibodies: 127 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 205.99 (req: >= 5)
Gene RIFs: 14 (req: > 3)
Antibodies: 127 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 4
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0